La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Genome Gestione

Gestione criteri di controllo 1/4

Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.

Informazioni chiave

Jisoo Pae

Amministratore delegato

n/a

Compenso totale

Percentuale dello stipendio del CEO	n/a
Mandato del CEO	8.9yrs
Proprietà del CEO	n/a
Durata media del management	5.7yrs
Durata media del Consiglio di amministrazione	Nessun dato

Aggiornamenti recenti sulla gestione

Nessun aggiornamento

Recent updates

Is Genome (KOSDAQ:314130) A Risky Investment?

Jul 03

Investors Still Aren't Entirely Convinced By Genome & Company's (KOSDAQ:314130) Revenues Despite 49% Price Jump

May 27

Positive Sentiment Still Eludes Genome & Company (KOSDAQ:314130) Following 25% Share Price Slump

Apr 11

Is Genome (KOSDAQ:314130) Using Debt In A Risky Way?

Mar 08

Genome (KOSDAQ:314130) Is In A Good Position To Deliver On Growth Plans

Mar 17

AMMINISTRATORE DELEGATO

Jisoo Pae

8.9yrs

Mandato

Mr. Jisoo Pae, M.D. is Director for Scioto Biosciences Inc. since 2022. He is Founder and Chief Executive Officer of Genome & Company since September 2015. Mr. Pae served as Psychiatrist at Seoul National...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Jisoo Pae	Founder & CEO	8.9yrs	Nessun dato	Nessun dato
Youngji Seo	Chief Executive Officer	2.4yrs	Nessun dato	Nessun dato
Yoo Seok Hong	Chief Executive Officer	1.3yrs	Nessun dato	3.17% ₩ 4.7b
Hansoo Park	Founder & CTO	9.3yrs	Nessun dato	Nessun dato
Sangkyun Kim	Chief Financial Officer	no data	Nessun dato	Nessun dato

5.7yrs

Durata media

Gestione esperta: Il team dirigenziale di A314130 è esperto e expertise (durata media dell'incarico 5.7 anni).

Genome Gestione

Gestione criteri di controllo 1/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Recent updates

Is Genome (KOSDAQ:314130) A Risky Investment?

Investors Still Aren't Entirely Convinced By Genome & Company's (KOSDAQ:314130) Revenues Despite 49% Price Jump

Positive Sentiment Still Eludes Genome & Company (KOSDAQ:314130) Following 25% Share Price Slump

Is Genome (KOSDAQ:314130) Using Debt In A Risky Way?

New minor risk - Share price stability

Genome & Company Announces Positive Topline Results from Phase 2 Clinical Trial of Combination of GEN-001 and Bavencio®? for the Treatment of Gastric Cancer Poster Presented at ASCO GI

New minor risk - Shareholder dilution

New minor risk - Share price stability

Genome & Company Announces Positive Results from Interim Analysis of Gen-001 Plus Avelumab (Bavencio®?) Phase II Trial

Third quarter 2022 earnings released: ₩860 loss per share (vs ₩714 loss in 3Q 2021)

Second quarter 2022 earnings released: ₩1,124 loss per share (vs ₩488 loss in 2Q 2021)

Genome & Company announced that it expects to receive KRW 18.8499274 billion in funding

First quarter 2022 earnings released: ₩673 loss per share (vs ₩549 loss in 1Q 2021)

Third quarter 2021 earnings: Revenues and EPS in line with analyst expectations

Genome & Company (KOSDAQ:A314130) agreed to acquire a 60% stake in List Biological Laboratories, Inc. for $27 million.

Genome (KOSDAQ:314130) Is In A Good Position To Deliver On Growth Plans

Genome and Company Signs Second Clinical Trial Collaboration and Supply Agreement (Phase 2) with Merck Kgaa, Darmstadt, Germany and Pfizer for Immuno-Oncology Microbiome Study

Genome & Company and Debiopharm Join Forces to Create New Highly Specific Therapies for Cancer Patients

New 90-day high: ₩72,400

New 90-day high: ₩52,600

Genome & Company Announces First Patient Dosed in Phase 1/1B Study of GEN-001

Genome & Company announced that it expects to receive KRW 19.99999001 billion in funding from Korea Development Bank, Investment Arm

AMMINISTRATORE DELEGATO

Mandato

Gruppo dirigente

Durata media